GTBP Historical Income Statement
| GTBP Stock | USD 2.34 0.16 6.40% |
Historical analysis of GT Biopharma income statement accounts such as Selling General Administrative of 8.8 M or Total Revenue of 0.0 can show how well GT Biopharma performed in making a profits. Evaluating GT Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of GT Biopharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining GT Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GT Biopharma is a good buy for the upcoming year.
GTBP |
About GTBP Income Statement Analysis
GT Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to GT Biopharma shareholders. The income statement also shows GTBP investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
GT Biopharma Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of GT Biopharma. It is also known as GT Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on GT Biopharma income statement and represents the costs associated with goods and services GT Biopharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from GT Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into GT Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.At this time, GT Biopharma's Depreciation And Amortization is relatively stable compared to the past year. As of 03/25/2025, Selling General Administrative is likely to grow to about 8.8 M, while Other Operating Expenses is likely to drop slightly above 12 M.
| 2024 | 2025 (projected) | Total Operating Expenses | 14.4M | 10.8M | Cost Of Revenue | 3.6K | 3.4K |
GT Biopharma income statement Correlations
Click cells to compare fundamentals
GT Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GT Biopharma income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 4K | 57.5M | 21.3M | 13.6M | 15.6M | 16.4M | |
| Interest Expense | 9.1M | 2.1M | 3.3M | 718K | 8K | 213K | |
| Selling General Administrative | 6.3M | 47.9M | 12.4M | 8.2M | 8.6M | 8.8M | |
| Other Operating Expenses | 6.8M | 57.5M | 21.3M | 13.6M | 15.6M | 12.0M | |
| Operating Income | (6.8M) | (57.5M) | (21.3M) | (13.6M) | (14.4M) | (15.1M) | |
| Ebit | (25.0M) | (115.0M) | (42.2M) | (7.6M) | (6.8M) | (7.2M) | |
| Research Development | 485K | 9.6M | 8.8M | 6.5M | 5.8M | 6.1M | |
| Ebitda | (25.0M) | (57.5M) | (21.0M) | 6.0M | (14.4M) | (15.1M) | |
| Total Operating Expenses | 6.8M | 57.5M | 21.3M | 13.6M | 14.4M | 10.8M | |
| Income Before Tax | (28.3M) | (58.0M) | (20.9M) | (7.6M) | (13.2M) | (13.8M) | |
| Total Other Income Expense Net | (21.5M) | (498K) | 373K | 6.0M | 1.2M | 1.3M | |
| Net Income | (31.6M) | (58.7M) | (20.5M) | (7.6M) | (13.2M) | (13.8M) | |
| Income Tax Expense | 3.3M | 680K | (381K) | (13.6K) | (12.2K) | (12.8K) | |
| Net Income Applicable To Common Shares | (259.2M) | (38.6M) | (28.3M) | (58.0M) | (52.2M) | (54.8M) | |
| Net Income From Continuing Ops | (28.3M) | (58.0M) | (20.9M) | (10.2M) | (13.2M) | (13.8M) | |
| Net Interest Income | (3.3M) | (680K) | 284K | 520K | 402K | 422.1K |
Pair Trading with GT Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against GTBP Stock
| 0.57 | GE | GE Aerospace | PairCorr |
| 0.53 | WM | Waste Management | PairCorr |
| 0.45 | WMT | Walmart | PairCorr |
| 0.44 | PLX | Protalix Biotherapeutics | PairCorr |
| 0.37 | MLSS | Milestone Scientific Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.